stockrowModerna, Inc.
MRNA Healthcare Biotechnology
Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.
- Revenue
- +2.11%
- EPS
- +7.51%
- Free cash flow
- +38.9%
- Total debt
- +1,765.6%
Quarter to June 2026, against a year earlier
Follow MRNA
Alert me
Moderna, Inc. (MRNA) Price to free cash flow
Moderna, Inc. has no meaningful price to free cash flow: its trailing twelve-month free cash flow is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 109× (December 2020) — the current reading is the lowest in ten years.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 15.4× | 100.58% |
| FY2021 | 7.7× | (62.23%) |
| FY2020 | 20.3× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 30 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| ROIV Roivant Sciences Ltd. compare | n/m |
| RVMD Revolution Medicines, Inc. compare | n/m |
| MRNA Moderna, Inc. | n/m |
| GMAB Genmab A/S Sponsored ADR compare | n/m |
| RPRX Royalty Pharma PLC compare | 22.8× |
| REGN Regeneron Pharmaceuticals, Inc. compare | 26.6× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 31.6× |
| VRTX Vertex Pharmaceuticals Incorporated compare | 37.4× |
| ARGX argenex SE compare | 40.7× |
| Biotechnology industry median | 22.6× |
| Healthcare sector median | 20.7× |
| Market median | 14.3× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on MRNA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement